Publication & Citation Trends
Most Cited Works
Publications
30 total
Abstract 410: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS.
Cited by 0
Semantic Scholar
Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
Cited by 1
OpenAlex
Abstract 4729: The reversible and selective FGFR2/3 inhibitor CGT4859 has superior target coverage of resistance mutations missed by leading FGFR inhibitors
Cited by 1
OpenAlex
Abstract P4-12-16: Identification of CGT4255 an EGFR sparing, ErbB2 clinical development candidate with activity across activating mutations in systemic and CNS tumors
Cited by 0
OpenAlex
Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
Cited by 0
Semantic Scholar
Abstract 5623: Identification of CGT4255 an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
Cited by 0
Semantic Scholar
Abstract P4-12-19: Preclinical Characterization of a Novel PI3Kα H1047R Mutant-Selective Inhibitor
Cited by 0
Semantic Scholar
Well-differentiated systemic mastocytosis: genetics, mast cell immunophenotypes, and KIT autophosphorylation.
Cited by 0
Semantic Scholar
Research Topics
Cancer, Hypoxia, and Metabolism
(8)
Fibroblast Growth Factor Research
(4)
Lung Cancer Treatments and Mutations
(3)
HER2/EGFR in Cancer Research
(3)
Sirtuins and Resveratrol in Medicine
(3)
Frequent Co-Authors
Affiliations
University of Science and Technology of China
University of Alberta
Pfizer (United States)
Cornell University
Hefei National Center for Physical Sciences at Nanoscale